IPA: Inhibition of platelet aggregation ... The combined use of antiplatelet drugs acting through different mechanisms is important in antithrombotic treatment of patients with cardiovascular ...

Selective Serotonin Reuptake Inhibitors ... or taking other medications that affect blood clotting. Recent studies have explored the relationship between SSRI use and platelet function, revealing ...

Eledon Pharmaceuticals has a promising anti-CD40L antibody for organ rejection prevention in transplantation. Learn more ...

Syndax Pharmaceuticals struggles with competitive pressures and market skepticism despite promising drugs and strong cash position. Read more on SNDX here.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...

NEW YORK — The US Food and Drug Administration (FDA ... in patients with androgenic alopecia include the application of platelet-rich plasma (PRP), stem cells, and exosomes, all of which ...

When evaluating antiplatelet drugs, an assay system that distinguishes ... and treatment may be required prior to platelet function testing. Regarding controlled inhibition of blood coagulation, such ...

Rigel Pharmaceuticals has enrolled the first patient in a Phase I trial to evaluate fostamatinib as a treatment for sickle ...

There are insufficient data to compare the medications in endovascular thrombectomies (EVTs) requiring emergent platelet inhibition. Objective To review our institution’s experience with cangrelor in ...

Trilaciclib significantly reduced chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer, which ...

Rigel Pharmaceuticals, Inc.  today announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of escalating doses of fostamatinib, the company's oral ...